同步转移性结直肠癌原发灶切除的预后价值:ARCAD数据库个体患者数据分析
基于ARCAD数据库8项一线系统治疗随机对照试验的3423例患者个体数据,分析原发灶切除(PTR)在同步转移性结直肠癌中的预后价值。未切除组中位总生存16.4个月,显著差于同步切除组(22.2个月,HR 1.60,95%CI 1.43-1.78)和异时转移组(22.4个月,HR 1.81,95%CI 1.58-2.07)。未切除组无进展生存亦显著更差。但切除原因未记录,结果可能存在偏倚, ongoing随机对照试验结果公布前, upfront PTR后系统治疗与 upfront系统治疗均为合适策略。
要点
- 未切除原发灶的同步mCRC患者中位OS 16.4个月,显著低于同步切除组22.2个月(HR 1.60)。
- 未切除组中位PFS亦显著更差:对比同步切除组HR 1.31,对比异时转移组HR 1.47。
- 切除原因未记录,结果可能受选择偏倚影响,需待ongoing RCT结果。
核心结论
- 在同步mCRC患者中,原发灶切除与更好的生存相关,但可能受选择偏倚影响。
研究设计与样本
- ARCAD数据库8项一线系统治疗随机对照试验的个体患者数据回顾性分析,共3423例。
- 未切除同步mCRC 710例(21%),切除同步mCRC 1705例(50%),异时mCRC 1008例(29%)。
主要发现
- 未切除组中位OS 16.4个月,同步切除组22.2个月(HR 1.60,95%CI 1.43-1.78),异时组22.4个月(HR 1.81,95%CI 1.58-2.07)。
- 未切除组中位PFS显著更差:对比同步切除组HR 1.31(95%CI 1.19-1.44),对比异时组HR 1.47(95%CI 1.30-1.66)。
- 多因素分析中上述关联仍显著。
临床怎么用
- 在ongoing随机对照试验结果公布前, upfront原发灶切除后系统治疗与 upfront系统治疗均可视为合适策略。
局限性
- 切除或未切除的原因未记录,结果可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Indication for primary tumour resection (PTR) in asymptomatic metastatic colorectal cancer (mCRC) patients is unclear. Previous retrospective analyses suggest a survival benefit for patients who underwent PTR. The aim was to evaluate the prognostic value of PTR in patients with synchronous mCRC by analysis of recent large RCTs including systemic therapy with modern targeted agents. Individual patient data (IPD) of 3423 patients enrolled into 8 randomised controlled trials (RCTs) with first-line systemic therapy in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analysed. The number of patients with unresected synchronous mCRC, resected synchronous mCRC and metachronous mCRC was 710 (21%), 1705 (50%) and 1008 (29%), respectively. Adjusting for age, gender, performance status (PS) and prior chemotherapy, the unresected group had a significantly worse median overall survival (16.4 m) compared with the synchronous resected (22.2 m; hazard ratio [HR] 1.60, 95% CI 1.43-1.78) and metachronous (22.4 m; HR 1.81, 95% CI 1.58-2.07) groups. Similarly, median progression-free survival was significantly worse for the unresected group compared with the synchronous resected (HR 1.31, 95% CI 1.19-1.44) and metachronous (HR 1.47, 95% CI 1.30-1.66) groups. In a multivariate analysis, the observed associations remained significant. This largest IPD analysis of mCRC trials to date demonstrates an improved survival in synchronous mCRC patients after PTR. These results may be subject to bias since reasons for (non)resection were not available. Until results of ongoing RCTs are available, both upfront PTR followed by systemic treatment and upfront systemic treatment are considered appropriate treatment strategies.
引用
- van Rooijen KL, Shi Q, Goey KKH, et al. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. Eur J Cancer. 2018. PMID: 29353165. doi:10.1016/j.ejca.2017.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。